U.S. Markets closed

Biophytis SA (BPTS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
11.90-0.33 (-2.70%)
At close: 11:19AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.23
Open11.80
Bid11.95 x 2200
Ask12.99 x 1800
Day's Range11.80 - 11.90
52 Week Range11.80 - 18.50
Volume1,206
Avg. Volume52,502
Market Cap139.428M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
    GlobeNewswire

    BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

    This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy dataThe Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it has recruited the 155th participant for Part 2 of its COVA Phase 2-3 study of Sarconeos (BIO101) in patients infected with COVID-19. Recruitment of the 155th participant allows for the independent Data Monitoring Committee (DMC) to conduct its second interim analysis, based on safety and efficacy data, for the continuation of the trial in case of favorable results. The Company is to report the recommendations of the DMC based on its review of the second interim analysis results by the end of Q2 2021. The DMC previously delivered a favorable opinion in March on the safety of Sarconeos (BIO101) in COVID-19 and recommended the continuation of the study into Part 2, following the scheduled interim analysis of the 50 participants in Part 1 of the COVA study. Recruitment into Part 2 of the study continues to proceed in France and Brazil to complete enrollment of 310 participants, with the aim of filing for Emergency Use Authorization with the US Food and Drug Administration (FDA) and Conditional Approval with the European Medicines Agency (EMA) in Q3 2021. The final study results are expected in Q3 2021, subject to any COVID-19-related delays and the impact of the pandemic. Stanislas Veillet, President and CEO of BIOPHYTIS, said: “Completion of recruitment of the 155th patient is an important milestone for BIOPHYTIS as we will be able to measure the therapeutic potential of Sarconeos (BIO101) in COVID-19. We are now looking forward to the second interim analysis, and hope the DMC will recommend the continuation of our Phase 2-3 COVA trial upon favorable review of the safety and efficacy data.” The COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global, multicenter, double-blind, placebo-controlled, group-sequential and adaptive design two-part study. This Phase 2-3 study assesses Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations of COVID-19. The 155 participants were recruited in 34 centers in 4 countries: the US, Brazil, France and Belgium. Part 1 of the COVA Study is a Phase 2 exploratory proof of concept study providing preliminary data on the safety, tolerability, and activity of Sarconeos (BIO101) in 50 patients with severe respiratory manifestations related to COVID-19. Part 2 of the COVA Study is a Phase 3 randomized study investigating the safety and efficacy of Sarconeos (BIO101) on the respiratory function of 310 COVID-19 participants, or up to 465 participants, including the 50 participants from Part 1 of the study. The final sample size will depend upon DMC recommendations from the second interim analysis. About BIOPHYTISBIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com. DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding BIOPHYTIS’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that BIOPHYTIS considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in participant recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to BIOPHYTIS or not currently considered material by BIOPHYTIS. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. BIOPHYTIS Contact for Investor RelationsEvelyne Nguyen, CFO evelyne.nguyen@biophytis.com Media contactLifeSci Advisors Sophie Baumont/Chris MaggosE: sophie@lifesciadvisors.com T: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Ligia Vela-ReidE: lvela-reid@lifesciadvisors.com

  • BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021
    GlobeNewswire

    BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021

    All ordinary and extraordinary resolutions have been adoptedPARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting. BIOPHYTIS’ combined AGM took place today behind closed doors, due to the COVID-19 pandemic. 2077 shareholders participated to the vote, holding collectively 24 994 687 shares, or a quorum of 22.37% and 22.82% of the voting rights. The 31 resolutions were approved at a majority of over 80% and were comprising in particular those ratifying the unconsolidated and consolidated accounts for fiscal year 2020 and the allocation of profit & loss for the fiscal year ended December 31, 2020 as well as extraordinary resolutions. Stanislas Veillet, President and CEO of BIOPHYTIS, said: “I am very pleased that all the resolutions of the Combined General Meeting were approved by a very large majority. I would like to warmly thank all shareholders for their exceptional commitment that made it possible for us to hold this General Meeting and for their confidence in BIOPHYTIS by supporting at a majority of over 80% each resolution put to the vote.” The results of the votes of the combined General Meeting will be available on BIOPHYTIS’ website from May 11, 2021, under the section - Investors - General Assembly:https://www.biophytis.com/en/action/assemblees-generales/assemblee-generale/ About BIOPHYTISBIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com. DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding BIOPHYTIS’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that BIOPHYTIS considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to BIOPHYTIS or not currently considered material by BIOPHYTIS. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website https://www.biophytis.com/. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. BIOPHYTIS Contact for Investor RelationsEvelyne Nguyen, CFO evelyne.nguyen@biophytis.com Media contactLife Sci Advisors Sophie Baumont/Chris MaggosE: sophie@lifesciadvisors.com T: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Ligia Vela-ReidE: lvela-reid@lifesciadvisors.com

  • Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
    GlobeNewswire

    Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders

    PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, informs its shareholders that the second combined Annual General Meeting (AGM) will be held on May 10, 2021 at 5PM CET, at Sorbonne University, 4 Place Jussieu – 75005 Paris, France. As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company’s Combined General Meeting will be held behind closed doors without the physical presence of its shareholders, in accordance with the provisions of the French Decree no 2021-255 of March 9, 2021. The notice of meeting, published in the French official legal bulletin Bulletin des Annonces Légales Obligatoires (BALO) n° 52, dated March 10, 2021 reminds the agenda, that stays unchanged. This notice includes information on how to attend and vote at the General Meeting, as well as the vote bulletin. All of the documents regarding this combined AGM (and mostly the text of resolutions) are available to shareholders on the Company’s website: www.biophytis.com, in the section Investors / General Assembly 2021: https://www.biophytis.com/en/action/assemblees-generales/assemblee-generale/. Shareholders are strongly encouraged to vote in advance of the shareholder meeting by postal mail, by appointing the Chairman of the meeting as your proxy or via the secure online platform VOTACCESS. On account of the possible effect of the Covid-19 pandemic on postal delivery times, it is recommended to return your voting forms as soon as practicable, or to vote via VOTACCESS. The unique proxi card is available on the Company’s website. Please note that the voting forms should be submitted no later than: For postal votes, the statutory deadlines apply: May 6 (4-day deadline before the AGM) for issuing instructions to the proxy holderMay 7 (3-day deadline before the AGM) for appointing the proxy VOTACCESS : May 9 at 3pm CET The shareholders are invited to consult the notice of the meeting, as published on the BALO (Bulletin des Annonces Légales Obligatoires) no 52, dated April 30, 2021, and available on the Company website for more details and precisions, depending on their shares (registered or bearer shares). The vote of shareholders who submitted their vote via the post, email or the Internet for the first combined AGM remains valid and counted for the general meeting on the second call. Shareholders who did not vote by post or proxy as part of the first combined AGM will be invited to send their forms and shareholder certificates: By post: CACEIS Corporate Trust, Service Assemblées Générales Centralisées - 14, rue Rouget de L’Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or About BIOPHYTISBiophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com. DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Biophytis Contact for Investor RelationsEvelyne Nguyen, CFO evelyne.nguyen@biophytis.comMedia contactLife Sci Advisors Sophie Baumont/Chris MaggosE: sophie@lifesciadvisors.comT: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Ligia Vela-ReidE: lvela-reid@lifesciadvisors.com